Relapsed / Refractory · Phase III; N=500; previously treated metastatic PDAC. Daraxonrasib vs investigator-choice chemotherapy. Dual primary endpoints: OS and PFS in RAS G12 population. · Overall population: median OS 13.2 vs 6.7 months (HR 0.40

RASolute 302

Primary setting: Relapsed / Refractory · Disease extent: Advanced / metastatic · Prior-treatment context: Relapsed / refractory or previously treated population; see trial-specific eligibility

Clinical question: Does daraxonrasib improve OS and PFS over investigator-choice chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma?

Overall population: median OS 13.2 vs 6.7 months (HR 0.40; P<0.001); median PFS 7.2 vs 3.6 months (HR 0.49; P<0.001). RAS G12 OS HR 0.40; PFS HR 0.45. · Registry:

Design, population and treatment

Phase III; N=500; previously treated metastatic PDAC. Daraxonrasib vs investigator-choice chemotherapy. Dual primary endpoints: OS and PFS in RAS G12 population.

Key efficacy outcome

13.2 · intervention

6.7

13.2 · comparator

Not calculable from median survival.

Grade ≥3 AEs 61.8% vs 69.6%; treatment-related discontinuation 1.2% vs 11.2%.

Safety and absolute effect

Median OS (months)

https://www.nejm.org/doi/10.1056/NEJMoa2605555

Interpretation and limitations

Current-practice context · 14 November 2026: Primary publication/abstract and trial identifier checked. Guideline-level current-practice mapping was not established in this publication-led batch; no NCCN citation provenance is claimed. Where detailed QoL, follow-up or toxicity data were not present in the retrieved abstract, they are not inferred.

Primary source

Primary publication · DOI: 10.1056/NEJMoa2605555